Relationship Between The Mutation Of Codon 12,13 In KRAS Gene And The Clinical And Pathological Characteristics Of Intrahepatic Cholangiocarcinoma

【Objective】 To explore the relationship between the mutation of codon 12,13 in KRAS gene and the clinical and pathological characteristics of intrahepatic cholangiocarcinoma.【Methods】 40 cases of paraffin-embedded tissue samples of intrahepatic cholangiocarcinoma in recent year were collected. After conventional deparaffinage, the DNA of paraffin-embedded tissue samples of intrahepatic cholangiocarcinoma was extracted, and then amplification and sequencing were conducted to the KRAS gene segments in the extracted DNA. The codon 12 and codon 13 of the frequently seen exon 2 in KRAS gene of intrahepatic cholangiocarcinoma were taken as the detection targets. Then, the mutation expression profiles of codon 12 and codon 13 of the exon 2 in KRAS gene were counted, the mutation rate of KRAS gene in intrahepatic cholangiocarcinoma was calculated, the clinicopathologic data of intrahepatic cholangiocarcinoma patients with KRAS gene mutation and that of patients without KRAS gene mutation were compared, and the relationship between the mutation of codon 12,13 in KRAS gene and the clinical and pathological characteristics of intrahepatic cholangiocarcinoma was analyzed.【Results】 Among the 40 paraffin-embedded tissue samples of intrahepatic cholangiocarcinoma, there were 13 cases(32.5%) of KRAS gene mutations, including 12 mutation cases(92.3%) in codon 12 and 1 mutation case(7.7%) in codon 13. Then, there were 8 GGT>GAT locus mutation cases(61.5%), 3 GGT>GTT locus mutation cases(23.1%), 1 GGT>GCT mutation case(7.7%) and 1 GGC>GAC locus mutation case(7.7%). The comparison of relevance degrees of the codon 12 and codon 13 mutations of KRAS gene with the patient gender, age, tumor size, tumor classification, tumor pathological pattern, differentiated degree, TNM staging, whether to combine hepatic calculus, and whether the CA199 and CEA in serum before operation increase among the various groups had no statistical significance(c2, P>0.05); but the mutations had relevance with the occurrence rates of lymphatic metastasis and distant metastasis of intrahepatic cholangiocarcinoma(c2, P<0.05).【Conclusion】 The KRAS gene mutation in intrahepatic cholangiocarcinoma mainly occurs in the codon 12, and the most frequently seen mutation locus is GGT>GAT lotus and GGT>GTT lotus. The KRAS gene mutation has relevance with the lymphatic metastasis and distant metastasis of intrahepatic cholangiocarcinoma, the intrahepatic cholangiocarcinoma with KRAS gene mutation has higher lymphatic metastasis and distant metastasis occurrence rates, and the KRAS gene mutation in clinical detection may be taken as the prognostic index to evaluate the intrahepatic cholangiocarcinoma.